Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Retained Earnings of $165.0 million for Q1 2026, up 571.43% year-over-year from $24.6 million in Q1 2025, and up 650.0% quarter-over-quarter from -$30.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Retained Earnings (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Retained Earnings history runs 6 years deep, the most recent figure standing at $165.0 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 571.43% year-over-year to $165.0 million; the TTM figure through Mar 2026 stood at $165.0 million (up 571.43% YoY), while the FY2025 annual figure was -$30.0 million, down 133.33% from the prior year.
- Retained Earnings for Q1 2026 stood at $165.0 million, up from -$30.0 million in the prior quarter.
- The five-year high for Retained Earnings was $1.3 billion in Q4 2022, with the low at -$346.0 million in Q3 2025.
- The 5-year median for Retained Earnings is -$31.5 million (2025), against an average of $103.2 million.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings slumped 133.33% in 2025, then soared 571.43% in 2026.
- Indivior Pharmaceuticals' Retained Earnings stood at $1.3 billion in 2022, then plunged by 122.1% to -$288.0 million in 2023, then soared by 131.25% to $90.0 million in 2024, then sank by 133.33% to -$30.0 million in 2025, then jumped by 650.0% to $165.0 million in 2026.
- Business Quant data shows INDV's Retained Earnings at $165.0 million in Q1 2026, -$30.0 million in Q4 2025, and -$346.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Indivior Pharmaceuticals | 4.51 Bn | 4.29 Bn | 294.00 Mn | -334.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -334.00 Mn |
| Mar 31, 2026 | 165.00 Mn |
| Dec 31, 2025 | -30.00 Mn |
| Sep 30, 2025 | -346.00 Mn |
| Jun 30, 2025 | -33.00 Mn |
| Mar 31, 2025 | -35.00 Mn |
| Dec 31, 2024 | 90.00 Mn |
| Dec 31, 2023 | -288.00 Mn |
| Dec 31, 2022 | 1.30 Bn |
| Dec 31, 2021 | -1.30 Bn |